NCT03492047View on ClinicalTrials.gov

N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

April 1, 2019

Study Completion Date

June 30, 2019

Conditions
Peripheral Neuropathy Due to Chemotherapy
Interventions
DIETARY_SUPPLEMENT

low dose N-acetylcysteine

N-acetylcysteine 600mg twice daily

DIETARY_SUPPLEMENT

high dose N-acetylcysteine

N-acetylcysteine 1200mg twice daily

DRUG

Paclitaxel

Paclitaxel 80mg /m2 IV

Trial Locations (1)

11566

AinShams University Hospitals, Cairo

All Listed Sponsors
collaborator

Nasser Institute For Research and Treatment

OTHER_GOV

lead

Ain Shams University

OTHER

NCT03492047 - N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients | Biotech Hunter | Biotech Hunter